Author

Myrthe Rouwette

Observed names: ROUWETTE, Myrthe, Rouwette, M., Rouwette, Myrthe

Observed institutions: Transnational University Limburg, Radboud University Medical Center, Synthon (Netherlands), Transnational University Limburg, Byondis BV (Netherlands), Hasselt University

ORCID: 0009-0007-5236-0453

Observed ORCID: 0009-0007-5236-0453

OpenAlex ID: A5089396219

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

2015 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al. · Molecular Cancer Therapeutics · 205

Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

2018 · Ruud Ubink, Eef H.C. Dirksen, et al. · Molecular Cancer Therapeutics · 48

PDF

Progressive Sensorineural Hearing Loss and Normal Vestibular Function in a Dutch DFNB7/11 Family with a Novel Mutation in TMC1

2010 · Anne-Martine R. de Heer, Rob W.J. Collin, et al. · Audiology and Neurotology · 41

Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform

2025 · Joanna Grudzinska-Goebel, Karin Benstein, et al. · Frontiers in Immunology · 28

PDF

Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis

2014 · Laura de Bock, Klaartje Somers, et al. · The Journal of Immunology · 26

Identification of coronin‐1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis

2013 · Myrthe Rouwette, Jean‐Paul Noben, et al. · Journal of Neurochemistry · 18

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al. · Molecular Cancer Therapeutics · 13

PDF

Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome

2012 · Myrthe Rouwette, Klaartje Somers, et al. · Journal of Neurochemistry · 13

PDF

Abstract 926: BYON3521, a novel effective and safe c-Met targeting antibody-drug conjugate

2021 · Patrick Groothuis, Danielle Jacobs, et al. · Cancer Research · 4

Abstract 6921: Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing

2026 · Mary J. van Helden, Genny Filliciotto, et al. · Cancer Research · 1

Abstract 5360: The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers

2015 · Willem Dokter, Miranda van der Lee, et al. · Cancer Research · 1

Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

2025 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

954 Phosphonate-antibody-drug conjugates: a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing

2025 · Mary JVan Helden, Genny Filiciotto, et al. · Journal for ImmunoTherapy of Cancer

PDF

Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate

2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate

2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate

2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

1160 Phosphonate-antibody-drug conjugates: a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing

2023 · Mary J van Helden, Ronald C Elgersma, et al. · Journal for ImmunoTherapy of Cancer

PDF

Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.

Supplementary Tables 1 through 3 and Supplementary Figures 1 through 6 from The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

2023 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al.

Supplementary Materials and Methods, Figures S1 - S4 and Tables S1 - S3 from Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

2023 · Ruud Ubink, Eef H.C. Dirksen, et al.

PDF

2023 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al.

Data from Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

2023 · Ruud Ubink, Eef H.C. Dirksen, et al.

Works count: 33

Citation count: 398

H-index: 8

I10-index: 8